Ginkgo Bioworks Holdings Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 181/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Sell, with the highest price target at 10.67.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ginkgo Bioworks Holdings Inc's Score
Industry at a Glance
Industry Ranking
181 / 404
Overall Ranking
319 / 4563
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Sell
Current Rating
10.667
Target Price
+13.48%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Ginkgo Bioworks Holdings Inc Highlights
StrengthsRisks
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Fairly Valued
The company’s latest PE is -1.36, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 31.33M shares, decreasing 0.01% quarter-over-quarter.
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Ticker SymbolDNA
CompanyGinkgo Bioworks Holdings Inc
CEOKelly (Jason)
Websitehttps://investors.ginkgobioworks.com/
FAQs
What is the current price of Ginkgo Bioworks Holdings Inc (DNA)?
The current price of Ginkgo Bioworks Holdings Inc (DNA) is 8.405.
What is the symbol of Ginkgo Bioworks Holdings Inc?
The ticker symbol of Ginkgo Bioworks Holdings Inc is DNA.
What is the 52-week high of Ginkgo Bioworks Holdings Inc?
The 52-week high of Ginkgo Bioworks Holdings Inc is 17.580.
What is the 52-week low of Ginkgo Bioworks Holdings Inc?
The 52-week low of Ginkgo Bioworks Holdings Inc is 5.000.
What is the market capitalization of Ginkgo Bioworks Holdings Inc?
The market capitalization of Ginkgo Bioworks Holdings Inc is 477.71M.
What is the net income of Ginkgo Bioworks Holdings Inc?
The net income of Ginkgo Bioworks Holdings Inc is -547.03M.
Is Ginkgo Bioworks Holdings Inc (DNA) currently rated as Buy, Hold, or Sell?
According to analysts, Ginkgo Bioworks Holdings Inc (DNA) has an overall rating of Sell, with a price target of 10.667.
What is the Earnings Per Share (EPS TTM) of Ginkgo Bioworks Holdings Inc (DNA)?
The Earnings Per Share (EPS TTM) of Ginkgo Bioworks Holdings Inc (DNA) is -6.189.